Dr. Ruzdijic added: "Also, as a part of HIRU corporation we will be able to test the potency of herbal extracts and herbal preparations on our human cancer cell lines. Just to remind, MindUp BioResearch group is working on establishment of resistant cancer human cell lines with intention to examine new therapeutic modalities in overcoming resistance to standard chemotherapy in the area of cancer treatment. In addition, we perform the measurement of the frequency of gene mutations and chromosomal aberrations (frequency of genomic instability) in genomes of patients with non-small cell lung cancer (NSCLC). In course of this research ten genes altered during NSCLC promotion and progression are identified. These genes may be potential biomarkers and useful for target therapy, as well as for testing and finding new therapies. Target therapy enables the application of personalized treatment, which again could improve the patient survival."
Furthermore, it will allow the medical team of MindUp to offer non competitive consulting services back to HTDS (company it acquired Mind Up from) and other interested parties for the limited scope of stem cell bank and rejuvenate medical procedures project(s).
The company intends to make regular timely announcements of its activities to its followers and shareholders.
To be included in HIRU's email database for press releases and industry updates, please subscribe at or opt in with your email address at this link http://www.minamargroup.com/updates/.
Safe Harbor Statement
Information in this news release may contain statements about future expectations, plans, prospects or performance of Hiru Corporation that constitute forward-looking statements for purposes of the Safe Harbor Provisions under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be", "expects", "may affect", "believed", "estimate", "project" and similar words and phrases are intended to identify such forward-looking statements. Hiru Corporation cautions you that any forward-looking information provided by or on behalf of Hiru Corporation is not a guarantee of future performance. None of the information in this press release constitutes or is intended as an offer to sell securities or investment advice of any kind. Hiru Corporation's actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hiru Corporation's control. In addition to those discussed in Hiru Corporation's press releases, public filings, and statements by Hiru Corporation's management, including, but not limited to, Hiru Corporation's estimate of the sufficiency of its existing capital resources, Hiru Corporation's ability to raise additional capital to fund future operations, Hiru Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities, and in identifying contracts which match Hiru Corporation's capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hiru Corporation does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.
SOURCE Hiru Corporation